Skip to main content

Table 2 Patient details

From: Deciphering molecular mechanisms underlying chemoresistance in relapsed AML patients: towards precision medicine overcoming drug resistance

 

Age

Sex

Diagnosis

Karyotype/Mutations

ELN risk score

WHO AML category

De-Novo/secondary AML

WBC at diagnosis

Extramedullary involvement

P1

27

Female

Jan 2019

T (10;11) (p11;q11), del (9) (q13q22) [3]/ Normal [17]

Intermediate

M4 - acute monoblastic/ monocytic leukemia

De novo

1.24 × 1000/mcl

No

P2

18

Female

Dec 2017

t(8;21)

Favorable

M1- AML without maturation

De novo

3.05 × 1000/mcl

No

GR1

38

Male

May 2016

Normal Karyotype, NPM1mut

Favorable

M2- AML with maturation

De novo

166 × 1000/mcl

No

GR2

62

Male

Sep 2018

Normal Karyotype, NPM1mut

Favorable

M1- AML without maturation

De novo

6.6 × 1000/mcl

No

GR3

69

Male

Jan 2017

Normal Karyotype

Intermediate

M2- AML with maturation

De novo

11.7 × 1000/mcl

No

GR4

63

Female

Dec 2010

Normal Karyotype

Intermediate

M1- AML without maturation

De novo

4.4 × 1000/mcl

No

GR5

28

Male

Oct 2013

t(8;21)

Favorable

M2- AML with maturation

De novo

25.8 × 1000/mcl

No